Neurotech International Ltd (NTI) - Net Assets

Latest as of December 2025: AU$5.88 Million AUD ≈ $4.16 Million USD

Based on the latest financial reports, Neurotech International Ltd (NTI) has net assets worth AU$5.88 Million AUD (≈ $4.16 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$6.81 Million ≈ $4.82 Million USD) and total liabilities (AU$932.85K ≈ $660.05K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NTI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$5.88 Million
% of Total Assets 86.3%
Annual Growth Rate 9.08%
5-Year Change -23.49%
10-Year Change -79.6%
Growth Volatility 359.91

Neurotech International Ltd - Net Assets Trend (2015–2025)

This chart illustrates how Neurotech International Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Neurotech International Ltd (NTI) total assets for the complete picture of this company's asset base.

Annual Net Assets for Neurotech International Ltd (2015–2025)

The table below shows the annual net assets of Neurotech International Ltd from 2015 to 2025. For live valuation and market cap data, see NTI market cap.

Year Net Assets Change
2025-06-30 AU$2.95 Million
≈ $2.09 Million
-75.17%
2024-06-30 AU$11.90 Million
≈ $8.42 Million
+200.32%
2023-06-30 AU$3.96 Million
≈ $2.80 Million
+177.06%
2022-06-30 AU$1.43 Million
≈ $1.01 Million
-62.97%
2021-06-30 AU$3.86 Million
≈ $2.73 Million
+697.48%
2020-06-30 AU$-646.29K
≈ $-457.29K
-317.30%
2019-06-30 AU$297.41K
≈ $210.44K
-92.97%
2018-06-30 AU$4.23 Million
≈ $2.99 Million
-1.49%
2017-06-30 AU$4.30 Million
≈ $3.04 Million
-70.34%
2016-06-30 AU$14.48 Million
≈ $10.25 Million
+1018.47%
2015-12-31 AU$1.29 Million
≈ $916.07K
--

Equity Component Analysis

This analysis shows how different components contribute to Neurotech International Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5098077200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$48.91 Million 1655.56%
Other Comprehensive Income AU$6.20 Million 209.72%
Other Components AU$1.00 0.00%
Total Equity AU$2.95 Million 100.00%

Neurotech International Ltd Competitors by Market Cap

The table below lists competitors of Neurotech International Ltd ranked by their market capitalization.

Company Market Cap
Mitra Pemuda Tbk PT
JK:MTRA
$11.01 Million
Hoth Therapeutics Inc
NASDAQ:HOTH
$11.02 Million
Ruffer Investment Company Limited
LSE:RICA
$11.04 Million
Weha Transportasi Indonesia TBK
JK:WEHA
$11.04 Million
B.A.G Films and Media Limited
NSE:BAGFILMS
$11.00 Million
Standard Industries Limited
NSE:SIL
$11.00 Million
Garibaldi Resources Corp.
V:GGI
$11.00 Million
Great Northern Minerals Ltd
AU:GNM
$11.00 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Neurotech International Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 11,898,687 to 2,954,549, a change of -8,944,138 (-75.2%).
  • Net loss of 10,598,859 reduced equity.
  • New share issuances of 429,526 increased equity.
  • Other comprehensive income decreased equity by 524,806.
  • Other factors increased equity by 1,750,001.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-10.60 Million -358.73%
Share Issuances AU$429.53K +14.54%
Other Comprehensive Income AU$-524.81K -17.76%
Other Changes AU$1.75 Million +59.23%
Total Change AU$- -75.17%

Book Value vs Market Value Analysis

This analysis compares Neurotech International Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.21x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.11x to 4.21x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-06-30 AU$0.11 AU$0.01 x
2017-06-30 AU$0.06 AU$0.01 x
2018-06-30 AU$0.04 AU$0.01 x
2019-06-30 AU$0.00 AU$0.01 x
2020-06-30 AU$0.00 AU$0.01 x
2021-06-30 AU$0.01 AU$0.01 x
2022-06-30 AU$0.00 AU$0.01 x
2023-06-30 AU$0.00 AU$0.01 x
2024-06-30 AU$0.01 AU$0.01 x
2025-06-30 AU$0.00 AU$0.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Neurotech International Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -358.73%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -433.60%
  • • Asset Turnover: 0.75x
  • • Equity Multiplier: 1.10x
  • Recent ROE (-358.73%) is below the historical average (-265.65%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -64.84% -390.01% 0.07x 2.54x AU$-968.88K
2016 -28.95% -1722.11% 0.01x 2.04x AU$-2.93 Million
2017 -93.87% -4565.50% 0.02x 1.15x AU$-4.46 Million
2018 -94.31% -13280.17% 0.01x 1.09x AU$-4.41 Million
2019 -1614.66% -2468.29% 0.30x 2.19x AU$-4.83 Million
2020 0.00% -2214.72% 0.96x 0.00x AU$-1.65 Million
2021 -192.43% -3604.58% 0.04x 1.30x AU$-7.82 Million
2022 -235.12% -8787.42% 0.02x 1.41x AU$-3.51 Million
2023 -196.67% -130759.17% 0.00x 1.34x AU$-8.19 Million
2024 -42.60% -258239.99% 0.00x 1.03x AU$-6.26 Million
2025 -358.73% -433.60% 0.75x 1.10x AU$-10.89 Million

Industry Comparison

This section compares Neurotech International Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $9,810,720
  • Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Neurotech International Ltd (NTI) AU$5.88 Million -64.84% 0.16x $11.01 Million
Adalta Ltd (1AD) $3.70 Million -162.25% 0.87x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $-1.33 Million 0.00% 0.00x $20.04 Million
ACRUX Ltd (ACR) $12.85 Million -73.71% 0.44x $3.20 Million
Actinogen Medical Ltd (ACW) $21.74 Million -43.69% 0.07x $105.70 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $15.45 Million
Arovella Therapeutics Ltd (ALA) $11.03 Million -40.87% 0.23x $58.08 Million
Anatara Lifesciences Ltd (ANR) $924.54K -218.83% 0.54x $1.57 Million
Alterity Therapeutics Ltd (ATH) $20.73 Million -6.40% 0.01x $76.95 Million
Amplia Therapeutics Ltd (ATX) $11.23 Million -30.16% 0.02x $50.82 Million
Avecho Biotechnology Ltd (AVE) $3.27 Million -95.48% 0.53x $28.59 Million

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$11.01 Million
AU$15.56 Million AUD
Market Cap Rank
#26629 Global
#1305 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.03
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more